Cellaria Inc and BioLamina pool expertise to support better biological and drug research.

02/11/2021 WAKEFIELD, MA: One of the biggest challenges in drug development and
personalized medicine is how to model the cellular microenvironment accurately. The
challenge applies to both cancer research and the use of induced Pluripotent Stem Cells
(iPSC) for tissue modeling, high-throughput drug screening, basic research, and
regenerative medicine applications. As the number of iPSC lines and our knowledge about
them increases, there is a growing concern that the process of iPSC generation via cell
reprogramming causes genetic aberrations, chromosomal rearrangements, and other
issues that appear during iPSC clonal expansion. Cellaria and BioLamina are pursuing this
challenge by collaborating to develop more defined reprogramming methods, large-scale
iPSC expansions, and lineage differentiation for human cells and animal cells for vertebrate
and non-vertebrate species.

The partnership will build on the broadly established methods from both companies for
iPSC reprogramming and expansion of cell culture protocols that produce cells with no
detectable short and long-term genetic deviations or changes compared to the starting cell
material. With those methods, Cellaria will use cells from its patient-specific cohorts, or
other animals, to establish functional and sustainable cell model systems. Cellaria iPSC
production ranges from millions to one billion cells. It supports a variety of applications for
customers, including studies of biological pathways, drug screening and development, and
investigating pharmacological and toxicological mechanisms of action. Cellaria’s cell models
also expand the available platforms on which researchers can build the next generation of
personalized therapies.

BioLamina provides human recombinant laminin, a crucial tissue culture substrate for the
generation and expansion of iPSCs, as well as specific differentiation with maintained
phenotypes with a reduced genetic drift. It is chemically defined and animal origin-free and
mimics the tissue-specific cell microenvironment. In turn, this provides more consistent and
reliable cellular responses and improves cell functionality.

“Cellaria guides drug researchers to understand individual patient responses to potential drug
therapies, paving the way for predictive, personalized medicine,” comments David Deems, CEO
of Cellaria. “Our authenticated cell models and in-depth cell data directly represent patients’
reality, resulting in timely and personalized decision making. This collaboration will enable us to
provide iPSCs that even more closely represent the original patient environment.”

“BioLamina has gained a lot of expertise in growth, maintenance and differentiation of different
primary cells. The laminins are the natural environment for cells in the body and it is a pleasure
to work with world leading experts at Cellaria to use them further to make top of the class tools
to be used for drug discovery,” comments Kristian Tryggvason, Founder at BioLamina.

About Cellaria Inc.

Cellaria Inc’s mission is to develop and build more informative disease cell models to
revolutionize and accelerate the search for a cure. The company provides a suite of
products and services that are actionable, replicable and that originate from a patient’s
unique specimens. With 7 years of research and development, Cellaria’s solutions better
enable disease researchers to select promising compounds and ultimately identify the most
effective treatment for each patient’s needs. This helps lead the research community to
more personalized therapeutics, revolutionizing and accelerating the search for a cure
and/or personalized treatments.

www.cellariainc.com or call 781-257-2679.

About BioLamina

BioLamina’s innovative products solve many of the technical problems associated with
maintaining human pluripotent stem cells in a naive state and enable to push these stem
cells towards different specialized cell types, such as neurons, heart cells, and liver cells.
Our flagship products, our biorelevant human recombinant laminin isoforms (Biolamininsä),
are defined cell culture matrices that successfully imitate the natural, cell-specific cell-matrix
interaction in the cell culture dish, allowing the cells to thrive and maintain their function. Our
products are a powerful resource for scientists working both within basic research as well as
in regenerative medicine companies with focus on cell therapy applications.

For more information: www.biolamina.com

Media Contact

Contact: Claire England, Covalent Bonds

Claire@covalentbonds.com

New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials

CHERRY HILL, N.J., April 22, 2021 (GLOBE NEWSWIRE) – Vyant Bio, Inc. (“Vyant” or the “Company”)  (Nasdaq: VYNT), an emerging leader in novel drug discovery techniques, announces a collaboration that  will seek to de-risk the development of small protein therapeutics. In partnership with Ordaōs Bio  (“Ordaōs”) and Cellaria, Inc. (“Cellaria”), the Company is unveiling a model for rapid iteration of  therapeutic design using artificial intelligence and in vitro ‘avatar clinical trials’ that will enable the design,  development, and testing of potential therapeutics on specific patient populations, during preclinical  development. The goal is to provide an early detection system of a drug’s efficacy in different patient  cohorts, prior to clinical trials.  

The collaboration capitalizes on the unique capabilities of each company to design, manufacture, and test  small-protein therapeutics that target multiple biomarkers derived from whole genome sequencing of  patient populations. Using proprietary AI, Ordaōs will generate in silico protein sequences, designed to  bind specific disease targets, and will serve as a blueprint for the collaborative team’s experts in in vitro and in vivo preclinical drug discovery, to produce the protein and rapidly iterate the structure using a  highly efficient expression system. Using Cellaria’s Patient Specific Cell Model Cohorts, the purified protein  will be critically evaluated for target binding and further optimized to improve performance across an  array of disease-specific genetic biomarker expressing cells. Once fully optimized by the team, Vyant Bio’s  objective will be to deliver regulatory readiness and a maximally de-risked drug candidate. The combined  solution will provide data and human-based insights not usually available until after a costly clinical trial. 

“Vyant Bio is committed to transforming the way that drugs are discovered by quickly adapting to exciting  new technologies and combining capabilities in ways that leverage their strengths,” stated Jay Roberts,  CEO of Vyant Bio. “Our collaboration with Ordaōs and Cellaria allows us all to work together to design and  develop superior therapeutics and position them to be as successful as possible before they get into the  clinic.” 

Cellaria Inc. uses cell biology in novel ways to provide insights into how a therapeutic may perform in  specific patient populations, prior to clinical trials. In this collaboration, Cellaria provides the means for  scientists to test how a drug will perform in a range of patient cohorts. The Cellaria in vitro and 3-D Models of tumor and metastatic niches are directly linked to a patient’s disease state and enable multiple  parametric deep data sets in genomics, proteomics, and combinatorial analysis.  

“Working with the Ordaōs and Vyant Bio teams has been incredibly important for us. Seeing the wealth  of patient data and cells used so seamlessly to inform and guide the design of a therapeutic is highly  rewarding,” stated David Deems, President and Founder of Cellaria Inc. “We are developing a repeatable  process that leverages well defined patient cohorts to learn as much as possible prior to embarking on a  clinical trial.” 

Ordaōs uses generative AI technology to accelerate the mini protein drug discovery and development  process. In this collaboration, Ordaōs provides a pipeline of digitally optimized therapeutics for further  development. The company was founded by David Longo, a Stanford and Harvard-trained AI and biotech  scientist, and Ulo Palm, MD, PhD, a 30-year veteran of clinical drug discovery and development at Allergan,  Novartis, and Schering Plough. 

“We are very excited about working with Vyant Bio and Cellaria to further our vision for transforming the  way we bring therapeutics to patients. At Ordaōs, we believe that designing, rather than discovering,  drugs is now possible with AI and will allow us to think bigger when we envision the impact we can have  on people’s lives.” said David Longo, CEO of Ordaōs. 

Ülo Palm, Ordaōs’ Chief Medical Officer, added that “the ultimate goal is to use modern AI to design the  next generation of highly effective and safe biologics for treating cancer and inflammatory diseases  thereby creating transformative treatment options for potentially millions of patients worldwide. We  expect that this new approach will significantly accelerate drug R&D overall and get the new drugs to  patients much faster than with the traditional drug development approach. Patients who suffer from  chronic and life-threatening diseases cannot wait. That is why this new collaboration is so important.” 

The three companies will continue to refine their strategies for drug design and development through a  series of projects targeting cancer, pancreatic, and autoimmune disorders. As the project evolves, the  therapeutic de-risking strategy will further incorporate the human-based biology and analytical software  of StemoniX, a wholly owned subsidiary of Vyant Bio. 

About Vyant Bio, Inc. 

Vyant Bio, Inc. (“Vyant Bio”) is emerging as an advanced biotechnology drug discovery company. With  capabilities in data, science (both biology and chemistry), engineering, and regulatory, we are rapidly  identifying small and large molecule therapeutics and derisking decision making through multiple in silico,  in vitro, and in vivo modalities. Leveraging these modalities, Vyant Bio is able to capitalize on repurposed  and novel compounds and then partner with others to further develop and commercialize valuable  therapeutics and new treatments for patients. Vyant Bio operates two wholly-owned subsidiaries,  StemoniX and vivoPharm and is empowering the discovery of new medicines through the convergence of  novel human biology and software technologies. 

StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPS) cell derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate,  and consistent, these human models enable scientists to conduct research quickly and economically with  improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations,  StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom  human iPSC-derived disease models at large scale for high-throughput screening. With leading-edge iPSC  technologies and data science, StemoniX is helping global institutions bring the most promising medicines  to patients. 

vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early  stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers.  vivoPharm is focused on precision and translational medicine to drive drug discovery and novel therapies.  vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound  libraries, and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for  Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation  of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities. 

About Ordaōs Bio 

Ordaōs employs a powerful proprietary AI engine and biological expertise to allow researchers to see  critical patterns and relationships in their data, unlocking previously unattainable and actionable insights  to design—rather than discover—novel therapeutic molecules. This will enable Ordaōs to accelerate  medical research, design complex therapeutic candidates and predict the outcomes of clinical trials. 

About Cellaria , Inc. 

Cellaria identifies disruptive ways to develop new in vitro and 3-D Models of tumors and metastatic niches  that are more directly linked to the patient’s disease state and enable multiple parametric deep data sets  in genomics, proteomics, and combinatorial analysis. Their capabilities include drug compound testing,  enrollment, and collection of patient specimens for model development, defining and monitoring clinically  relevant characteristics for each clinical disease category and across patient cohorts. This approach  provides more in-depth insight into the heterogeneity of patient characteristics in a disease category and  provides information about the stability and utility of the patient-specific model over time. 

For more information, please visit www.vyantbio.com; www.ordaos.bio and www.cellariainc.com. Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities  Litigation Reform Act of 1995. All statements pertaining to Vyant Bio Inc.’s (formerly Cancer Genetics, Inc.)  expectations regarding future financial and/or operating results, and potential for our services, future  revenues or growth, or the potential for future collaborations and strategic transactions in this press  release constitute forward-looking statements. 

Any statements that are not historical fact (including, but not limited to, statements that contain words  such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to  be forward-looking statements. Forward-looking statements involve risks and uncertainties, including,  without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, achieve 

profitability and increase sales of our pre-clinical services, maintain our existing customer base and avoid  cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs,  realize the anticipated benefits of the merger with StemoniX, Inc., and other risks discussed in the Vyant  Bio, Inc.’s Form 10-K for the year ended December 31, 2020, along with other filings with the Securities  and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio,  Inc. disclaims any obligation to update these forward-looking statements. 

Vyant Bio Investor Contact 

Jennifer K. Zimmons. Ph.D. 

Investor Relations  

Zimmons International Communications, Inc.  

Email: jzimmons@zimmonsic.com 

Phone: +1.917.214.3514

Successful award of NIH R01 funding paves the way for accelerated Precision Therapeutics.

11/17/2020 WAKEFIELD, MA: ​Cellaria Inc (Wakefield, MA, USA) and the Spring Lab, Northeastern University, announce the successful receipt of a National Institutes of Health (NIH) R01 grant to extend and advance the application of innovative new photomedicine-based therapies for hard-to-treat cancers. The grant highlights the close working relationship of the two organizations and will provide $3.2M funding to develop precision therapeutics closely tailored to the requirements of specific patient populations. Cellaria’s contribution to the partnership is next generation, patient-derived, customized cell models that boost the effectiveness of ​in vitro studies, helping researchers to identify where the technology can have the most impact. Dr Bryan Spring, Assistant Professor of Biomedical Physics credits Cellaria with a vital role in accelerating his research.

“We’ve demonstrated proof of concept and seen significant interest from clinicians,” said Dr Spring. “However, we initially targeted just a single ovarian cancer biomarker. To capture the heterogeneity of the disease and efficiently study multiple biomarkers we needed to upgrade our cell models. Developing new models in-house would have taken years and instead we chose to work with Cellaria. This has really accelerated progress by providing rapid access to rigorously characterized cell models for specific molecular subtypes and patient populations.”

Dr Spring’s research focuses on the use of antibody-photosensitizer conjugates to make cancer cells susceptible to light-induced destruction, targeting microscopic cancer cell deposits left behind by conventional therapies. Primary areas of application are pancreatic and ovarian cancer. With these cancers, cells left behind by surgery and other conventional therapies can metastasize in the peritoneal cavity and abdomen, attacking other organs and increasing the severity of the disease. The new NIH research grant is entitled “Multiplexed and dynamically targeted photoimmunotherapy of heterogeneous, chemoresistant micrometastases guided by online in vivo optical imaging of cell-surface biomarkers”.

Cellaria provides cell models, complete with comprehensive omics data, that help the researchers to determine which biomarkers are most actionable when it comes to targeting drug resistant cells and applying the photomedicine. These cell models robustly represent the full heterogeneity of the cancers, which is essential for the development of precision therapies. Dr Spring has been using Powder, a high grade serous ovarian cancer cell model developed from the carcinoma of a 65 – 69 Caucasian, stage IV patient. New models for pancreatic cancer have recently been added to the Cellaria portfolio. All have a robustly authenticated lineage and are provided with protocols to maintain specific biomarker expression. Cellaria’s unrivalled expertise in cell line growth, stabilization and characterization underpin the company’s ability to supply customised models that enable researchers to identify the specific biomarkers of most relevance to their work.

“Cellaria have all the -omics in place and are highly responsive in terms of refining models to our requirements,” said Dr Spring. “The Cellaria team are experts in their field and great to work with. The bottom line is that via this collaboration we get to concentrate on our science, rather than the tools we need to support it, which is just as we prefer it.”

About Cellaria Inc.

Cellaria Inc’s mission is to develop and build more informative disease cell models to revolutionize and accelerate the search for a cure. The company provides a suite of products and services that are actionable, replicable and that originate from a patient’s unique specimens. ​With 7 years of research and development, Cellaria’s solutions better enable disease researchers to select promising compounds and ultimately identify the most effective treatment for each patient’s needs. This helps lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure and/or personalized treatments.

First presentation of data using Cellaria’s proprietary patient-specific models of the tumor microenvironment used to study tumor growth, metastasis.

06/24/2020 WAKEFIELD, MA: Cellaria announces today it is presenting data on the value of modeling the metastatic niche, and the benefits of using patient-derived cancer cell models, mesenchymal stem cells (MSCs), and optimization of oxygen level and extracellular matrix (ECM) to study antitumor drug response, personalized therapy, and disease mechanisms. The data, featured in a poster at 2020 AACR Annual Meeting II, results from Cellaria’s spheroid system using five cancer cell models (pancreatic, lung adenocarcinoma, colon adenocarcinoma, endometrioid ovarian and high-grade serous carcinoma). With this 3D system, Cellaria is addressing an unmet need to improve predictions of the safety and efficacy of new drugs in preclinical testing and clinical trials.

By using patient-specific cell models, translational scientists are able to go beyond traditional cell lines, to address the complexity and individuality of the disease and identify treatments that better meet the needs of each patient.  Specificity in cell models enables researchers to derive the answers they need earlier in the drug development life cycle and with a continuous, direct connection to the patient.

“This data demonstrates the power of using patient specific cell models in a 3D format to model the tumor microenvironment and gain more actionable information from drug screening studies” comments David Deems, CEO, Cellaria Inc. “By using specific model patient populations that maintain their heterogeneity and individuality, users can test targets on our highly characterized cell models and select the mutation profile that is most important to their research.”

To see the data, please download the poster here. For more information on Cellaria Inc and its patient-specific cell models, please visit cellariainc.com or call 978-720-8051.

Download the Poster

About Cellaria Inc.

Cellaria Inc’s mission is to develop and build more informative disease cell models to revolutionize and accelerate the search for a cure. The company provides a suite of products and services that are actionable, replicable and that originate from a patient’s unique specimens. Cellaria’s solutions better enable disease researchers to select promising compounds and ultimately identify the most effective treatment for each patient’s needs. This helps lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure and/or personalized treatments.

By growing cells in unrealistic liquids, they may have inadvertently skewed the results of their experiments.

Partnership targets broader availability of new models and tools for cancer research

Cambridge, Mass. and Natick, Mass., May 02, 2018 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the formation of a strategic partnership with SBH Sciences (SBH). The companies will collaborate to evaluate drug response using Cellaria’s patient-specific cell models and cell culture media products with SBH’s cell-based assay services. As a result, SBH will be able to accelerate its efforts to generate drug response data for larger sets of patients that are clinically diagnosed with the same disease.